Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
2022 · NEJM Evidence · 986 citations
https://doi.org/10.1056/evidoa2200015
C
Choong‐kun Lee
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
170
Papers
4.7K
Citations
27
h-index
53
i10-index
Choong‐kun Lee is an academic researcher from Yonsei University. The author has contributed to research in topics: Gastric Cancer Management and Outcomes & Cholangiocarcinoma and Gallbladder Cancer Studies & Pancreatic and Hepatic Oncology Research. The author has an h-index of 27, co-authored 145 publications.
ORCID: 0000-0001-5151-5096Papers by this author
worksPembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
2023 · The Lancet · 891 citations
https://doi.org/10.1016/s0140-6736(23)00727-4
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)
2022 · The Lancet. Gastroenterology & hepatology · 115 citations
https://doi.org/10.1016/s2468-1253(22)00335-1
A MST1–FOXO1 cascade establishes endothelial tip cell polarity and facilitates sprouting angiogenesis
2019 · Nature Communications · 102 citations
https://doi.org/10.1038/s41467-019-08773-2
Large Language Models: A Guide for Radiologists
2024 · Korean Journal of Radiology · 70 citations
https://doi.org/10.3348/kjr.2023.0997
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
2022 · Nature Communications · 51 citations
https://doi.org/10.1038/s41467-022-33267-z
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat